GSK-PAR 29060 651 (BRL – 02960)

A 12 week, double-blind, fixed dose comparison of 20 and 40mg daily of paroxetine and placebo in Patients suffering from Post-traumatic Stress Disorder (PTSD).
PAR 29060 651 (BRL – 02960)
Post-Traumatic Stress Disorder
Phase 3
The data from this study is provided in combined datasets containing data from other paroxetine studies. A raw dataset, an annotated case report form, a reporting and analysis plan, a clinical study report, and a protocol are not available for this study. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
December 2014